Platelet aggregation pathway protein targets

The entry "Platelet aggregation pathway targets" does not refer to a single canonical target but rather encompasses a group of key proteins and receptors implicated in the initiation and propagation of platelet aggregation. This biological process involves multiple well-characterized molecular targets, including the integrin glycoprotein IIb/IIIa (GPIIb/IIIa), P2Y1 and P2Y12 purinergic receptors, thromboxane A2 receptor (TXA2R/TP), protease-activated receptors (primarily PAR1, PAR4), and glycoprotein VI (GPVI)[1][3][4][6][7][8]. Collectively, these proteins facilitate platelet activation, granule release, structural transformation, and ultimately aggregation necessary for hemostasis and thrombosis. Each is a proper therapeutic target, and drugs have been developed to selectively modulate several of them (notably P2Y12, GPIIb/IIIa, PAR1, TXA2R). The phrase as stated is overly broad and does not conform to a unique, specific target molecule, making it unsuitable as a singular therapeutic target entry.

Other names

Platelet aggregation pathway proteinsPlatelet aggregation pathway componentsPlatelet aggregation receptorsPlatelet activation pathway proteins

P2Y12 inhibition (blocks ADP-induced platelet activation), GPIIb/IIIa inhibition (prevents fibrinogen crosslinking and aggregation), PAR-1 antagonism (inhibits thrombin-induced activation), COX-1 inhibition (pre_vents TXA2 synthesis, e.g., aspirin), Other agonist/receptor blockade (e.g., TP, GPVI)